相关实验视频
Updated: Jun 11, 2025

12:10
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
7.6K
确定长期前列腺癌的结果 积极监测患者没有早期疾病进展:减缓或停止监测的影响
Kevin Shee1, James Nie1, Janet E Cowan1
1Department of Urology, Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA.
European urology oncology
|September 28, 2024
概括
前列腺癌 (PCa) 患者的积极监测 (AS) 稳定了5年,显示了适度的升级率和低转移风险. 诸如年龄,BMI和活检阳性等因素会影响升级,这表明有可能减少AS协议的强度.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 在瘤学瘤学.
- 癌症监测 癌症监测
背景情况:
- 积极监测 (AS) 是低度前列腺癌 (PCa) 的标准,但对于稳定的患者缺乏明确的指导方针.
- 对于长期稳定AS的PCa患者的长期结果存在有限的数据.
研究的目的:
- 调查前列腺癌患者在没有初始进展的情况下在积极监测下长期的结果.
- 为了确定与稳定的AS患者疾病升级相关的风险因素.
主要方法:
- 包括格里森等级组1PCa的男性,5年以上没有AS进展,以及10年以上的随访.
- 评估结果:升级,主要升级,治疗进展,转移,PCa特定存活率和总生存率.
- 使用Cox比例危险回归来分析患者特征和升级风险.
主要成果:
- 在15年后,无升级生存率为21%,无重大升级生存率为61%,无治疗生存率为73%.
- 在15年内,无转移生存率为98%和总生存率为95%;PCa特定生存率为100%.
- 诊断年份,年龄较大,BMI较高和活检核心阳性预测升级;年龄较大和PSA密度预测重大升级.
结论:
- 前列腺癌患者在AS稳定5年经历了适度的升级率和15年低转移/死亡率.
- 年龄较大,BMI增加,活检阳性和PSA密度与升级风险增加有关.
- 降低AS协议的强度可能有利于选择没有进展的患者.
更多相关视频
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.0K
13:19Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
16.5K
相关概念视频
Cancer Survival Analysis
329
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
329
Actuarial Approach
63
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
63